<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04477239</url>
  </required_header>
  <id_info>
    <org_study_id>GRRES-2020-1551</org_study_id>
    <nct_id>NCT04477239</nct_id>
  </id_info>
  <brief_title>Diagnostic Performance of Urinary Gluten Immunogenic Peptides in Monitoring the Adherence to Gluten-free Diet.</brief_title>
  <official_title>A Randomized, Triple-blind, Placebo-controlled, Crossover Clinical Trial on the Diagnostic Performance of Gluten Immunogenic Peptides in the Evaluation of Gluten-free Diet Adherence: the GRRES Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the GRRES study is to assess the clinical usefulness of urinary gluten
      immunogenic peptides test as a marker of gluten-free diet adherence using the rapid
      immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A strict and permanent gluten free diet (GFD) is the only effective treatment resulting in
      full clinical, serological and histological remission, avoiding long-term complications in
      celiac disease (CD) patients. Gluten immunogenic peptides (GIP) are fragments of gluten
      proteins resistant to gastrointestinal digestion and detectable in urine after intestinal
      digestion, providing direct evidence of recent gluten ingestion. A significant variability in
      the amount of excreted urinary GIP has been reported in individuals administered with similar
      doses of gluten and, so far, inadequate information is available about the amount of excreted
      GIP in subjects ingesting traces or low amount of gluten. This is an important issue, as even
      a strict GFD could be contaminated by traces of gluten, e.g. in wheat starch and processed
      food. The aim of this study is to assess the clinical usefulness of urinary GIP as a marker
      of GFD adherence using a rapid immunochromatographic assay based on anti-gliadin 33-mer
      monoclonal antibodies. This is a prospective, randomized, triple-blind, placebo-controlled,
      crossover clinical trial. In this study, healthy volunteers following a normal diet will be
      requested to be on strict GFD for 5 days. On day 4th, participants will be requested to
      collect a baseline urine sample and in case of a negative GIP test result they will be
      assigned to ingest a specific dose of purified gluten incorporated in a capsule (0 mg, 10 mg,
      50 mg, 100 mg, 500 mg and 1000 mg, according to randomization). Participants will be
      requested to collect urine samples in a container and take a 5 mL aliquote for the GIP test
      at the 9th and 24th hour from the time of the administration of the dose. During the
      collection, volunteers will also be requested to record the volume of the excreted urine and
      to store the collected urine at 4°C. Urine tubes will be stored at -20°C until the
      quantitative evaluation of GIP. GIP test will be performed using the rapid
      immunochromatographic assay based on anti-gliadin 33-mer monoclonal antibodies iVYCHECK GIP
      Urine™ test (Biomedal, Spain) according to the manufacturer's instructions.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>Randomization will be performed using a random sequence generator to conceal the sequence from the rest of the researchers and to ensure that only the investigator who will manipulate the gluten doses will know the allocation pertaining to each individual. This investigator will not carry out any assessment or any other intervention during the trial period. Until study completion, the enrolled subjects, the clinicians and the person who will perform the statistical analysis will be blinded to the group assigned.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-response relationship between the amount of gluten intake and urinary excretion of GIP.</measure>
    <time_frame>3 months</time_frame>
    <description>The primary objective of the study is to verify the usefulness of the quantitative GIP assay in urine as biomarker of adherence to the gluten-free diet in terms of dose-response relationship between the amount of ingested gluten and urinary excretion of GIP in a group of healthy volunteers.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of one capsule of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purified gluten (10 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of capsules containing 10 mg of purified gluten.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purified gluten (50 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of capsules containing 50 mg of purified gluten.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purified gluten (100 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of capsules containing 100 mg of purified gluten.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purified gluten (500 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of capsules containing 500 mg of purified gluten.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Purified gluten (1000 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of capsules containing 1000 mg of purified gluten.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Gluten (behaviour)</intervention_name>
    <description>Gluten is a protein normally present in the daily diet of healthy volunteers not suffering from gluten related disorders, in far greater quantities (10-20 g/day) than those used in this study (10 mg-1 g/day).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Purified gluten (10 mg)</arm_group_label>
    <arm_group_label>Purified gluten (100 mg)</arm_group_label>
    <arm_group_label>Purified gluten (1000 mg)</arm_group_label>
    <arm_group_label>Purified gluten (50 mg)</arm_group_label>
    <arm_group_label>Purified gluten (500 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Placebo (behaviour)</intervention_name>
    <description>Placebo is composed of pregelatinized maize starch Ph.Eur. 97.5%; magnesium stearate Ph.Eur. 1.5%; micronized silica Ph.Eur. 0.5%; Micronized talc Ph.Eur. 0.5% (NOT containing preservatives, colorings, or gluten).</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Purified gluten (10 mg)</arm_group_label>
    <arm_group_label>Purified gluten (100 mg)</arm_group_label>
    <arm_group_label>Purified gluten (1000 mg)</arm_group_label>
    <arm_group_label>Purified gluten (50 mg)</arm_group_label>
    <arm_group_label>Purified gluten (500 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteers

          -  20-40 years old

          -  written informed consent

        Exclusion Criteria:

          -  type 1 diabetes

          -  chronic or acute inflammatory diseases of the gastrointestinal tract (CD, non-celiac
             gluten sensitivity, Crohn's disease, ulcerative colitis, food allergy, acute
             gastroenteritis ≤ 4 weeks prior to the study start)

          -  pregnancy or lactation

          -  chronic intake of medications and supplements

          -  refusal/withdrawal of written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Catassi, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Univeristà Politecnica delle Marche, Ancona, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elena Lionetti, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univeristà Politecnica delle Marche, Ancona, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simona Gatti, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Univeristà Politecnica delle Marche, Ancona, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiara Monachesi, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Univeristà Politecnica delle Marche, Ancona, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anil K Verma, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Univeristà Politecnica delle Marche, Ancona, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Catassi, MD, MPH</last_name>
    <phone>+39 071 5962364</phone>
    <email>c.catassi@univpm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elena Lionetti, MD, PHD</last_name>
    <phone>+39 071 596 2372</phone>
    <email>m.e.lionetti@univpm.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Department of Pediatrics</name>
      <address>
        <city>Ancona</city>
        <zip>60123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Moreno ML, Cebolla Á, Muñoz-Suano A, Carrillo-Carrion C, Comino I, Pizarro Á, León F, Rodríguez-Herrera A, Sousa C. Detection of gluten immunogenic peptides in the urine of patients with coeliac disease reveals transgressions in the gluten-free diet and incomplete mucosal healing. Gut. 2017 Feb;66(2):250-257. doi: 10.1136/gutjnl-2015-310148. Epub 2015 Nov 25.</citation>
    <PMID>26608460</PMID>
  </reference>
  <reference>
    <citation>Stefanolo JP, Tálamo M, Dodds S, de la Paz Temprano M, Costa AF, Moreno ML, Pinto-Sánchez MI, Smecuol E, Vázquez H, Gonzalez A, Niveloni SI, Mauriño E, Verdu EF, Bai JC. Real-World Gluten Exposure in Patients With Celiac Disease on Gluten-Free Diets, Determined From Gliadin Immunogenic Peptides in Urine and Fecal Samples. Clin Gastroenterol Hepatol. 2020 Mar 23. pii: S1542-3565(20)30350-5. doi: 10.1016/j.cgh.2020.03.038. [Epub ahead of print]</citation>
    <PMID>32217152</PMID>
  </reference>
  <reference>
    <citation>Silvester JA, Comino I, Kelly CP, Sousa C, Duerksen DR; DOGGIE BAG Study Group. Most Patients With Celiac Disease on Gluten-Free Diets Consume Measurable Amounts of Gluten. Gastroenterology. 2020 Apr;158(5):1497-1499.e1. doi: 10.1053/j.gastro.2019.12.016. Epub 2019 Dec 19.</citation>
    <PMID>31866245</PMID>
  </reference>
  <reference>
    <citation>Verma AK, Gatti S, Galeazzi T, Monachesi C, Padella L, Baldo GD, Annibali R, Lionetti E, Catassi C. Gluten Contamination in Naturally or Labeled Gluten-Free Products Marketed in Italy. Nutrients. 2017 Feb 7;9(2). pii: E115. doi: 10.3390/nu9020115.</citation>
    <PMID>28178205</PMID>
  </reference>
  <reference>
    <citation>Catassi C, Fabiani E, Iacono G, D'Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, Pianelli G, Gesuita R, Carle F, Mandolesi A, Bearzi I, Fasano A. A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. Am J Clin Nutr. 2007 Jan;85(1):160-6.</citation>
    <PMID>17209192</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Politecnica delle Marche</investigator_affiliation>
    <investigator_full_name>Carlo Catassi, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gluten-free diet</keyword>
  <keyword>Gluten immunogenic peptides</keyword>
  <keyword>Gluten contamination</keyword>
  <keyword>Gluten</keyword>
  <keyword>Urine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

